Clinical trials: Antipsychotic
Schizophrenia
D-serine Monotherapy for Schizophrenia
A first generation of clinical studies, performed during the last decade, demonstrates that adjuvant treatment with compounds that enhance NMDAR-mediated neurotransmission due to their agonistic activity at the NMDAR-associated…
- Trial name
- NCT00816894
- Testing
- D-serine, Olanzapine
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Herzog Hospital
Schizophrenia, Psychotic Disorders
Bergen Psychosis Project 2 - The Best Intro Study
In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses and followed for 12 months.
- Trial name
- BP2 (NCT01446328)
- Testing
- Amisulpride, Aripiprazole, Olanzapine
- Where
- 4 sites in Austria, Norway
- Volunteers
- 151 people
- Sponsor
- Haukeland University Hospital
Diabetes
Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics
Antipsychotic medicines used to treat mental illnesses have been associated with effects on blood sugar control. Laboratory studies have shown that certain medications in particular may alter how insulin works.
- Trial name
- NCT01411930
- Testing
- Intramuscular olanzapine, aripiprazole, Intramuscular aripiprazole, olanzapine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Child Behavior Disorders
Safer Use of Antipsychotics in Youth
This study tests the effectiveness of an intervention treatment algorithm vs. usual care control in a practical clinical trial. Control arm providers will receive a standard medication alert in the electronic medical record (EMR)…
- Trial name
- SUAY (NCT03448575)
- Testing
- Control - Provider Medication Alert Only, Intervention - Alert + CAP Review AND Enhanced BH Access
- Where
- 4 sites in United States
- Volunteers
- 733 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Schizophrenia
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.
- Trial name
- METS (NCT00816907)
- Testing
- Metformin
- Where
- 16 sites in United States
- Volunteers
- 146 people
- Sponsor
- National Institute of Mental Health (NIMH)
Acute Psychotic Episode, Schizophrenia
Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia
This is an observational study describing the real-life antipsychotic treatment during the hospitalisation of the patients due to acute psychotic episode.
- Trial name
- NCT01491412
- Where
- 14 sites in Hungary, Latvia and 1 more
- Volunteers
- 503 people
- Sponsor
- AstraZeneca
Dementia, Behavior
Deprescribing Antipsychotics in Long-Term Care
Aggressive behaviours in long-term care (LTC) is a difficult health care issue to manage. One method that has been over-used is the prescription of antipsychotics for the behaviours and psychological symptoms of dementia (BPSD).
- Trial name
- NCT02958800
- Testing
- Intervention
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- McMaster University
Schizophrenia, Schizoaffective Disorder
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00222807
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Depression, Bipolar
An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
This study uses polysomnographs(PSG) to investigate sleep patterns in patients with bipolar depression. This is a double-blind, placebo-controlled, study of ziprasidone that is added to patients current medications.
- Trial name
- NCT00835107
- Testing
- ziprasidone hydrochloride
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Queen's University
Delayed Antipsychotic Treatment, Pharmacological Factors and Individual Factors
Assessment of Pain During Intramuscular Injection Delay in Adult Psychiatry
Since psychiatry is still too often confronted with a dichotomy between psyche and soma, the assessment of pain and anxiety at RMI is still rarely done (Willer et al., 1982).
- Trial name
- evadoulim (NCT04784572)
- Testing
- first injection delay and second injection delay
- Where
- France
- Volunteers
- 393 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Schizophrenia, Renal Impairment
A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function
The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of 3 mg extended release paliperidone (ER OROSÃ' paliperidone) in patients with varying degrees of renal impairment (mild, moderate, and severe)…
- Trial name
- NCT00791401
- Testing
- ER OROS Paliperidone
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation…
- Trial name
- NCT02469155
- Testing
- ITI-007, Risperidone
- Where
- 11 sites in United States
- Volunteers
- 696 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Psychotic Disorder
Deprescribing Antipsychotics: a Multiple Case Study
The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be…
- Trial name
- DEPRESC (NCT07343193)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Antipsychotics Weight Gain
Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile
This is an open label study to prospectively evaluate the effect of adjunct use of Aripiprazole, as an agent to improve metabolic profile and induce weight loss in patients established on atypical antipsychotics (Olanzapine…
- Trial name
- NCT02949752
- Testing
- Aripiprazole
- Where
- Singapore
- Volunteers
- 67 people
- Sponsor
- Institute of Mental Health, Singapore
Schizophrenia
Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia
The purpose of this study is to document the clinical benefit of quetiapine (Seroquel) sustained release (SR) after switching from another ongoing antipsychotic treatment, regardless of the reason for the switch.
- Trial name
- NCT00234377
- Testing
- Seroquel SR
- Where
- 27 sites in Canada, Finland and 2 more
- Volunteers
- 550 people
- Sponsor
- AstraZeneca
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2_3Y (NCT02526030)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Aggression
Risperidone Augmentation for Treatment-Resistant Aggression in ADHD
Primary objectives: 1. To assess the short-term efficacy of risperidone augmentation for treatment-resistant aggression in children with ADHD. 2.
- Trial name
- NCT00297739
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Armenteros, Jorge L., M.D., P.A.
Schizophrenia
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.
- Trial name
- NCT00333177
- Testing
- Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles